This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Scared of a September Lull? Play 6 ETFs
by Sanghamitra Saha
These ETFs may perform well in ill-famed September due to solid fundamentals.
5 ETFs to Play in July
by Sanghamitra Saha
Investors may tap these five ETFs for gains as President Trump aims the first shot in the trade war.
5 Safe and Sound ETF Strategies for 2H
by Sweta Killa
After a bumpy ride in the first half of the year, global stocks are bouncing back despite the trade war fears.
How to Build a Winning ETF Portfolio Amid Trade War Fears
by Sweta Killa
We have highlighted some strategies that could prove extremely beneficial for investors in a choppy market.
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
Why These Small Cap Biotech ETFs are Soaring
by Neena Mishra
These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.
Best and Worst ETFs of Last Week
by Sweta Killa
Several ETFs saw a huge decline while a few stood tall in the market turbulence.
4 Sector ETFs to Ride on Strong Beat Ratios
by Sanghamitra Saha
Sector ETFs with strong beat ratios in fourth-quarter earnings.
Biotech Crushing the Market: Best ETFs & Stocks YTD
by Sweta Killa
The recent developments are fueling growth in the biotech companies, leading to a rally in their share prices and impressive levels of momentum in biotech ETFs.
Biotech ETF (BBC) Hits New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?